Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Q32 Bio Inc. (Nasdaq: QTTB), a clinical-stage biotechnology firm, has announced the pricing of an underwritten public offering totaling $200 million. The offering includes shares of common stock and pre-funded warrants, aimed at raising capital to support its development pipeline. The company specializes in therapies targeting alopecia areata and other autoimmune and inflammatory conditions. The details of the offering, including the number of shares and warrants, were not specified in the announcement. This move is part of Q32 Bio's strategy to fund ongoing clinical trials and research activities. The market reaction to this announcement has not been specified, but such offerings typically impact the company's stock price and investor sentiment. The company’s stock is traded on Nasdaq under the ticker QTTB.